Scottish Medicines Consortium accepted Adalimumab (Humira) for adolescents that do not respond to other DMARDs

An excerpt from the Drug Advice issued by the Scottish Medicines Consortium on adalimumab (Humira): adalimumab (Humira)  is  accepted  for  restricted  use  in  NHS  Scotland,  in  combination  with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13-17  years  who  have  an  inadequate  response  to  one  or more  disease-modifying  anti-rheumatic drugs […]

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos